21 research outputs found
Additional file 2: Table S2. of Predicting multi-class responses to preoperative chemoradiotherapy in rectal cancer patients
List of TO and MI genes used as the features for the prediction model. (XLSX 20.9 kb
Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy
<div><p>Purpose</p><p>To evaluate the prognostic impact of the lymph node ratio (LNR) in ypStage III rectal cancer patients who were treated with neoadjuvant chemoradiotherapy (NCRT).</p><p>Materials and Methods</p><p>We retrospectively reviewed the data of 638 consecutive patients who underwent NCRT followed by total mesorectal excision, and postoperative adjuvant chemotherapy for rectal cancer from 2004 to 2011. Of these, 125 patients were positive for lymph node (LN) metastasis and were analyzed in this study.</p><p>Results</p><p>The median numbers of examined and metastatic LNs were 17 and 2, respectively, and the median LNR was 0.143 (range, 0.02–1). Median follow-up time was 55 months. In multivariate analyses, LNR was an independent prognostic factor for overall survival (OS) (hazard ratio [HR] 2.17, <i>p</i> = 0.041), disease-free survival (DFS) (HR 2.28, <i>p</i> = 0.005), and distant metastasis-free survival (DMFS) (HR 2.30, <i>p</i> = 0.010). When ypN1 patients were divided into low (low LNR ypN1 group) and high LNR (high LNR ypN1 group) according to a cut-off value of 0.152, the high LNR ypN1 group had poorer OS (<i>p</i> = 0.043) and DFS (<i>p</i> = 0.056) compared with the low LNR ypN1 group. And there were no differences between the high LNR ypN1 group and the ypN2 group in terms of the OS (<i>p</i> = 0.703) and DFS (<i>p</i> = 0.831).</p><p>Conclusions</p><p>For ypN-positive rectal cancer patients, the LNR was a more effective prognostic marker than the ypN stage, circumferential resection margin, or tumor regression grade after NCRT, and could be used to discern the high-risk group among ypN1 patients.</p></div
Oncologic and surgical outcomes in colorectal cancer patients with liver cirrhosis: A propensity-matched study - Fig 2
<p><b>Kaplan-Meier plots of overall survival between LC group and non-LC group a) overall, b) stage 0 and I, c) stage II, d) stage III and e) stage IV</b>.</p
Baseline characteristics of patients with liver cirrhosis.
<p>Baseline characteristics of patients with liver cirrhosis.</p
Kaplan-Meier plots of overall survival in LC group according to cancer stage and MELD-Na score.
<p>Kaplan-Meier plots of overall survival in LC group according to cancer stage and MELD-Na score.</p
Kaplan-Meier curves for (A) overall survival and (B) disease-free survival for all patients.
<p>Kaplan-Meier curves for (A) overall survival and (B) disease-free survival for all patients.</p
A comparison of recurrence between LC and non-LC group except patients with TNM stage IV.
<p>A comparison of recurrence between LC and non-LC group except patients with TNM stage IV.</p
Prognostic factors of 5-year survival by univariate analysis.
<p>Prognostic factors of 5-year survival by univariate analysis.</p
Compared with surgical outcomes and complications between LC and non-LC group.
<p>Compared with surgical outcomes and complications between LC and non-LC group.</p
Previously reported lymph node ratio studies of rectal cancer patients who underwent preoperative chemoradiotherapy.
<p>NR, not reported; CSS, cancer-specific survival. Other abbreviations as in Tables <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0138728#pone.0138728.t001" target="_blank">1</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0138728#pone.0138728.t002" target="_blank">2</a>.</p><p>Previously reported lymph node ratio studies of rectal cancer patients who underwent preoperative chemoradiotherapy.</p